Bio-Medpoint

bio-medpoint’s new coronary artery disease (cad) detection system is set to revolutionize heart disease prevention. tests using this new method were 94% accurate in revealing study participants with cad compared to 42% accuracy with the framingham risk score (frs). currently the only way to predict a patient’s likelihood of getting heart disease is by patient history, or the frs which estimates the chances a person will have a cardiac event in the next 10 years. unfortunately, these have low accuracy. meanwhile, cad kills 370,000 americans a year and costs the nation $109 billion each year. early detection can lead to improved treatment — saving lives, improving the quality of life, and reducing the heavy financial expense of this disease. to tackle the problem, a leading research university approached prediction from a different direction with remarkable results. bio-medpoint’s screening tool uses a small sample of blood serum— either from the vein or a finger-stick— and passes it